Bladder Cancer

Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.

The FDA approves enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, significantly improving survival rates post-surgery.

New data reveals detalimogene's promising efficacy and safety in treating high-risk bladder cancer, offering hope for improved patient outcomes.

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

UGN-103 shows promising 77.8% efficacy in treating recurrent low-grade bladder cancer, paving the way for a potential FDA approval.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

A new study reveals that combining TAR-200 with cetrelimab significantly improves treatment outcomes for muscle-invasive bladder cancer patients.

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies enhancing patient outcomes.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.

Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs different treatment paths.

Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder cancer.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.